MwanzoGNLX • NASDAQ
add
Genelux Corp
Bei iliyotangulia
$ 2.42
Bei za siku
$ 2.36 - $ 2.54
Bei za mwaka
$ 1.60 - $ 5.89
Thamani ya kampuni katika soko
93.58M USD
Wastani wa hisa zilizouzwa
elfu 193.01
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 7.82M | -3.78% |
Mapato halisi | -7.49M | 4.56% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.21 | 27.59% |
EBITDA | -7.76M | 3.41% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 35.10M | 78.85% |
Jumla ya mali | 38.98M | 57.99% |
Jumla ya dhima | 9.14M | -4.72% |
Jumla ya hisa | 29.85M | — |
hisa zilizosalia | 37.30M | — |
Uwiano wa bei na thamani | 3.02 | — |
Faida inayotokana na mali | -53.02% | — |
Faida inayotokana mtaji | -65.38% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -7.49M | 4.56% |
Pesa kutokana na shughuli | -5.44M | -24.83% |
Pesa kutokana na uwekezaji | 3.51M | 307.51% |
Pesa kutokana na ufadhili | 9.57M | 1,290.55% |
Mabadiliko halisi ya pesa taslimu | 7.64M | 242.64% |
Mtiririko huru wa pesa | -2.66M | -103.16% |
Kuhusu
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Ilianzishwa
2001
Makao Makuu
Tovuti
Wafanyakazi
24
